Neurology lives in the office visit. After several years of E/M guideline revisions and a new complexity add-on code, most practices have not fully rebuilt the financial case for the work they already do.
Key Takeaways
- The 2021 AMA E/M guideline revisions moved level selection from encounter-count to medical decision making or total time – a change that benefits cognitively complex specialties like neurology when documentation is built to support it.
- Add-on code G2211, payable on 99202-99215 and since 2026 also on home visit codes, is designed for the ongoing care relationship – which describes most neurology follow-up encounters – and remains undercaptured in many practices.
- The 2026 CMS conversion factor is $33.40 for non-APM practices, a modest improvement, but the value of office visits still depends on level selection accuracy and G2211 eligibility documentation.
- An E/M coding audit on a trailing six months often reveals consistent under-leveling or G2211 non-capture at a scale that outweighs any single contract renegotiation.
Neurology is among the most evaluation-and-management-intensive specialties in medicine. New patients arrive with complex, undifferentiated presentations. Follow-up patients carry chronic conditions – epilepsy, Parkinson’s disease, multiple sclerosis, migraine – that require ongoing assessment of symptom burden, medication response, and functional change. The cognitive load of a single neurology encounter is rarely in dispute. What is in dispute, in most practice billing departments, is whether the documentation consistently captures it.
The 2021 AMA revisions to office visit E/M guidelines replaced the old history-and-physical element counting with a simpler framework: level the visit by medical decision making (MDM) or total time, your choice. For neurology, this was a structural improvement. Complex MDM – multiple diagnoses, prescription drug management, data review from outside sources – is the routine, not the exception. The revision also removed the face-to-face time restriction: time now includes all work on the date of the encounter, including chart review before the patient arrives and notes completed after they leave. A practice that updated its documentation templates and trained its neurologists on the new framework captured the benefit. Many did not.
Layered on top of that change is G2211, the complexity add-on code that CMS introduced in 2024 after years of advocacy by primary care and cognitive specialties. The code is payable alongside 99202 through 99215 for encounters where the visit is part of an ongoing care relationship and the complexity of the patient’s condition is inherent to that relationship – not episodic, but continuous. Neurology follow-up visits for chronic conditions fit that description almost by definition. Yet G2211 capture rates in many neurology practices remain well below what the patient panel would support, because the documentation language required to justify it was never built into the note template.
What G2211 Actually Pays and What It Requires
Under the 2026 physician fee schedule, G2211 adds roughly $16 to an office visit for non-facility settings. That sounds modest until you apply it to volume. A four-neurologist practice seeing 120 follow-up visits per physician per month has roughly 5,760 follow-up encounters per year. If G2211 applies to even half – a conservative estimate given the nature of neurology chronic disease management – the annual revenue difference is close to $46,000 before any adjustment for payer mix. Most commercial plans follow Medicare on this code; a few lag by a year or two.
CMS has been clear about what the code requires: the visit must be part of an ongoing care relationship, and that relationship must be reflected in the documentation. A boilerplate note that could belong to any encounter does not support it. A note that references treatment history, prior medication adjustments, and the longitudinal trajectory of the patient’s condition – language that most neurologists write naturally but often do not preserve in a way the billing system can find – does support it. The documentation gap, not the clinical gap, is what limits capture.
The 2021 E/M revision and G2211 together shifted the payment equation toward cognitive specialties. Most neurology practices have not yet rebuilt their documentation to collect what the new rules allow.
E/M Level Distribution and the Under-Leveling Pattern
When we audit trailing billing data in a neurology practice, the distribution of E/M levels almost always shows a clustering at 99213 and 99214 that does not match the clinical record. Neurologists treating epilepsy patients with multiple anti-seizure medications, adjusting dosing based on serum levels and seizure diaries, reviewing outside imaging and outside records – these are 99215 encounters by any reading of the MDM table. They bill at 99214 because the note was not built to document the complexity that was clinically present.
The same pattern appears in new patient visits. A new patient referred for cognitive decline evaluation, arriving with extensive prior workup, neuropsychological testing results, and a family history that requires collateral history from a caregiver present at the visit – that is 99205. It often bills at 99204 because the note template does not prompt for the documentation elements that distinguish the levels under the current framework.
The revenue impact of one level of under-leveling across new and established visits is meaningful and computable. The more important point is that it does not require any change in clinical practice. The work is already happening. The documentation needs to reflect it accurately.
What to Audit and in What Order
A coding audit in a neurology practice that has not been touched since before 2021 should examine four things:
- E/M level distribution by visit type and neurologist. Run it for the trailing twelve months and compare the distribution to national neurology benchmarks available through CMS utilization data. Significant deviation below the benchmark is a documentation problem, not a risk problem.
- G2211 capture rate. What percentage of 99213-99215 follow-up visits include G2211? Cross-reference against your diagnosis mix – how many active patients have a chronic diagnosis that qualifies for the ongoing care relationship framing?
- Time-based documentation completeness. If your neurologists have shifted to time-based leveling, is total time consistently documented and is it the right time? The code for the level needs to match the total time documented.
- Payer acceptance of G2211. Build a report by payer showing G2211 acceptance versus denial rates. Some commercial payers require a modifier or have a lag in policy adoption. Identifying the denials early allows targeted appeals and contract-level follow-up.
The Compliance Dimension
Coding audits in neurology carry a compliance overlay that practices should take seriously. The same data analytics that identify under-leveling also identify over-leveling, and CMS and its contractors use similar tools on claim data. The goal of a coding review is accuracy in both directions, not maximum level selection. A practice that upgrades documentation quality to support 99215 encounters is in a defensible position. A practice that assigns 99215 to encounters the record does not support is not, regardless of what the patient’s condition actually is. These rules and their application vary by Medicare Administrative Contractor, and state and payer-specific rules add layers; any high-stakes coding change should be reviewed by qualified health law counsel before implementation.
From the Field
A three-neurologist private practice in the Mid-Atlantic had not touched its note templates or coding policies since 2019. The E/M level distribution showed 78 percent of established visits at 99213 or 99214 and G2211 capture below five percent. The practice was seeing a high proportion of chronic MS and epilepsy patients – exactly the population for which G2211 was designed. Our fractional CFO engagement pulled twelve months of billing data, mapped the distribution against CMS neurology utilization benchmarks, and identified a documentation gap rather than a clinical one: the templates prompted for symptom status but not for the medication management and longitudinal assessment language that supports higher MDM levels and G2211. Rather than hand over a report, we sat with each neurologist’s medical assistant to rebuild the note template, worked with the billing coordinator to set up a G2211 eligibility flag in the practice management system, and ran a payer-by-payer acceptance report for the new code combination. Twelve months later, G2211 capture was above 40 percent and the average E/M level on established visits had risen by approximately 0.4 levels. The practice never changed who it saw or how it practiced.
Consulting Versus Fractional Execution
A competent coding consultant can run the audit, identify the documentation gaps, and produce a template redesign. If your practice has a billing manager and a medical assistant team that can implement and sustain the change, that is often the most economical path, and we will tell you so. The plan is not the problem in most practices.
The problem is that template redesign requires buy-in from each neurologist, implementation support for the medical assistants who set up the note, and ongoing monitoring to confirm the habit took hold rather than drifting back to prior patterns within sixty days. That is ongoing inside work with your staff, not a deliverable. A fractional executive does the analysis and then does the implementation: sitting in on the chart review with each provider, rebuilding the template in your EHR, training the billing coordinator on the new G2211 flag, and pulling the monthly capture report until the number stabilizes. Be careful about firms that call themselves fractional executives but deliver a report and a template and consider the engagement complete. The test is whether they will be in your systems, with your staff, until the metric moves and holds.
Sources
- CMS, Calendar Year 2026 Medicare Physician Fee Schedule Final Rule — https://www.cms.gov/newsroom/fact-sheets/calendar-year-cy-2026-medicare-physician-fee-schedule-final-rule
- CMS, HCPCS G2211 Frequently Asked Questions — https://www.cms.gov/files/document/hcpcs-g2211-faq.pdf
- CMS, MLN Matters MM13473 – How to Use the Office Visit Complexity Add-On Code G2211 — https://www.cms.gov/files/document/mm13473-how-use-office-and-outpatient-evaluation-and-management-visit-complexity-add-code-g2211.pdf
- MGMA, 2025 Provider Compensation and Productivity Data Report — https://www.mgma.com/2025-provider-compensation
More in the Neurology Series
- Neurology Infusion Suite Economics and the Buy-and-Bill Risk Equation — how to evaluate infusion suite economics before you sign a drug purchasing agreement.
- In-Office Neurodiagnostics: EEG, EMG, and the Business Case for Doing Them Right — how to run an in-office neurodiagnostic program that survives a payer audit.
- Neurology Access and Referral Management: What Long Wait Times Are Actually Costing You — the operational and financial cost of long neurology wait times and how to move the number.
- Telehealth and Staffing Models for a Cognitive Specialty — how to build a neurology telehealth and staffing model that is financially sound and operationally stable.